Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy

• Date:
  Monday, 25 July 2011, All day
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

A transatlantic two-day workshop co-chaired with the United States Food and Drug Administration (FDA) on drug-related progressive multifocal leukoencephalopathy (PML).

Documents

Workshop proceedings - Transatlantic workshop on drug-related progressive multifocal leukoencephalopathy (PML)

Reference Number: EMA/674403/2011

Programme - Transatlantic workshop: Drug-related progressive multifocal leukoencephalopathy (PML)

DraftReference Number: EMA/262331/2011

Invitation for expressions of interest - Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy (PML)

Reference Number: EMA/97508/2011

List of participants - Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy (PML)

Reference Number: EMA/582655/2011

Presentation - Welcome, PML - Balancing risks and benefits - the patients' view, Christoph Thalheim

Presentation - The possible mechanisms of the disease, Eugene Major

Presentation - The outcomes of drug-induced PML, Joseph Berger

Presentation - Natalizumab (Tysabri) and PML - the current figures, Brigitte Keller-Stanislawski

Presentation - The relationship between PML-rituximab and other immunobiologicals: an overview, Renaud Du Pasquier

Presentation - The risk in transplanted patients, Marco Tuccori

Presentation - Activities in USA, the experience of FDA Neurology Division, Russel Katz

Presentation - PML: Risk communication in the EU, Rafe Suvarna

Presentation - Changes in the incidence of PML in Tysabri-treated patiens, Alice Hughes

Presentation - A common case definition for PML, Dirk Mentzer

Presentation - The Italian natalizumab registry, G. Tedeschi

Presentation - The TYSEDMUS Study, Christian Confavreux

Presentation - Industry Experience with PML, Carmen Bozic

Presentation - Development of models for testing possible treatments, Igor Koralnik

Presentation - Discovery and development of PML treatments, Teresa Compton

Presentation - Evidence about plasma exchange in natalizumab related PML, Ralf Gold

Presentation - Immune Reconstitution Inflammatory Syndrome, Joseph Berger

Presentation - PML development, Heinz Wiendl

Presentation - Diagnosing PML, Joseph Berger

Presentation - Viral subtypes and the development of the disease: what is the evidence, Igor Koralnik

Presentation - The research in the field: Where to progress?, Eugene Major

Presentation - Regulators initiative, research agenda, Ana Hidalgo

Presentation - Research Agendas, Eugene Major

Presentation - The Interface of Academia and Clinical Practice, Joseph Berger

Presentation - PML consortium - industry, Susan Goelz

Presentation - Challenges and opportunities from public private partnerships, Richard Bergstrà¶m

Presentation - The importance of clarity in relationships and transparency, Henry FItt

Presentation - Drug Safety Surveillance Initiatives, Gerald Dal Pan

Presentation - How to facilitate the communicationsdata exchange, Janice Soreth

Presentation - Public funding of research - EU perspective, Stefanie Prilla

Presentation - Public funding of research - US, Eugene Major

Presentation - The role of the pharmaceutical industry, Sophie Banzet

Presentation - Public Private Partnerships as funders, Hugh Laverty

Presentation - EU Regulators perspective, Peter Arlett

Presentation - US Regulators perspective, Russell Katz

Presentation - Industry PML consortium view, Sophie Banzet

Presentation - PML London Clinical Researchers perspective, Igor Koralnik

Presentation - Benefits of Public Health, Eugene Major

Presentation - Discussion 'progress for the benefit of public health', Ralf Gold

Presentation - What patients and caregivers want to happen now - priorities for action, Christoph Thalheim

Presentation - PML Final Conclusions, Peter Arlett

Multimedia